Neurology
MSC therapy or HSCT in multiple sclerosis — which question are you actually asking?
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
These are two very different interventions with very different evidence bases, risks and eligibility rules. Confusing them is the most common mistake we see.
- Medically reviewed by:
- Prof. Dr. Erdal Karaöz, PhD
- Last reviewed:
- Next review:
The short answer
Autologous haematopoietic stem cell transplantation (AHSCT) is an intensive, well-studied treatment for aggressive relapsing MS, delivered in transplant centres and carrying real mortality risk. MSC therapy is a low-intensity, immunomodulatory approach still under investigation, with no comparable disease-modifying evidence. If you have aggressive relapsing disease, the AHSCT conversation belongs with a neurologist first.
Who this decision applies to
Usually appropriate to discuss
- Confirmed MS with a current neurologist letter and recent MRI
- Clear understanding that MSC therapy and AHSCT are not interchangeable
- Disease-modifying therapy decisions already discussed with the treating team
- Willingness to be redirected if AHSCT is the better-evidenced route
Not appropriate right now
- Patients seeking MSC therapy instead of an indicated AHSCT referral
- Progressive disease with severe fixed disability and no inflammatory activity
- Anyone told they can stop disease-modifying therapy to qualify
- Diagnoses that have not been confirmed with MRI and specialist review
Evidence at a glance
The same five questions we ask of every indication, answered for this one.
| Question | Answer | What that means here |
|---|---|---|
| Human studies published? | Yes | Human MSC trials in MS are published, mostly phase 1/2 and safety-focused. |
| Randomised controlled trials? | Limited | Randomised MSC data exist but are small; AHSCT by contrast has randomised evidence. |
| Objective outcome measures? | Yes | EDSS, relapse rate and MRI lesion activity are reported. |
| Long-term follow-up (≥12 months)? | Limited | Long-term MSC follow-up is sparse; AHSCT cohorts have multi-year data. |
| Approved as a routine therapy? | No | MSC therapy is not an approved MS treatment; AHSCT is established in selected patients. |
How these judgements are made: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.
Options compared, including doing nothing
| Option | What it can realistically do | Main trade-off |
|---|---|---|
| Licensed disease-modifying therapy | Proven relapse and lesion reduction | Ongoing medication, monitoring and side effects |
| AHSCT in a transplant centre | Strongest evidence in aggressive relapsing MS | Chemotherapy conditioning, infection risk, mortality risk |
| MSC therapy | Investigational immunomodulation; safety acceptable in published series | No proven effect on disability progression |
| Symptomatic and rehabilitation care | Improves function and quality of life | Does not change the underlying disease |
How the decision is made in practice
- We read the neurologist's letter and MRI report before offering an opinion.
- We classify the disease course, because relapsing and progressive MS lead to different recommendations.
- Where AHSCT criteria appear to be met, we say so and encourage that referral first.
- If MSC therapy is discussed, it is framed as adjunctive with defined measures at 3, 6 and 12 months.
- Disease-modifying therapy continues unless the treating neurologist changes it.
When we decline, and why
- Requests to substitute MSC therapy for an indicated AHSCT pathway
- Requests to stop disease-modifying therapy
- Severe progressive disability where no plausible benefit exists
- Absence of specialist confirmation of the diagnosis
Declining is a normal outcome of assessment, not a failure of it. See how candidacy and redirection work.
Questions worth asking any clinic
- Am I a candidate for AHSCT, and if not, why not?
- What is the specific mechanism claimed here, and which human trials support it?
- Will my neurologist receive the treatment record and follow-up data?
- What outcome would count as failure, and what happens then?
Frequently asked questions
Sources
- mesenchymal stem cells multiple sclerosis randomized trial — MSC trials in MS.
- autologous hematopoietic stem cell transplantation multiple sclerosis randomized — Randomised AHSCT evidence in aggressive relapsing MS.
- mesenchymal stromal cells multiple sclerosis — Registered MSC trials in MS.
Citation practice and source hierarchy: How we evaluate evidence.
Related clinical questions
- Neurological indications we treat
- What the MSC evidence base actually shows
- Regulatory status by country
- Autoimmune follow-up schedule
Want this reviewed for your own case?
Send your diagnosis, imaging and medication list. If the answer is no, we will say so and explain why.
How to cite this page
This page's evidence table is published under CC BY 4.0. Reuse it with attribution and a link back.
| Style | Citation |
|---|---|
| APA | StemCell Longevita. (2026). MSC therapy or HSCT in multiple sclerosis. StemCell Longevita. https://stemcelllongevita.com/clinical-decisions/multiple-sclerosis-msc-versus-hsct |
| Vancouver | StemCell Longevita. MSC therapy or HSCT in multiple sclerosis [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/clinical-decisions/multiple-sclerosis-msc-versus-hsct |
BibTeX:
@techreport{longevita_multiple_sclerosis_msc_versus_hsct_2026,
title = {MSC therapy or HSCT in multiple sclerosis},
author = {{StemCell Longevita}},
institution = {StemCell Longevita},
year = {2026},
url = {https://stemcelllongevita.com/clinical-decisions/multiple-sclerosis-msc-versus-hsct},
urldate = {2026-08-23}
}Structured data: The evidence table on this page is also published as a machine-readable dataset descriptor. /cite